Suven Life Sciences begins Phase-2b trial of Ropanicant for depression, following promising Phase-2a safety and efficacy results.

• Ropanicant targets α4β2 nAChR receptors, showing rapid antidepressant effects in earlier trials with a good safety profile.
• Phase-2b trial is placebo-controlled, double-blinded, and conducted exclusively in the U.S. under FDA supervision.
• Suven emphasizes innovation and commitment to advancing treatment options for patients with Major Depressive Disorder (MDD).